Murex (Canada) launches deoxyribonucleic (DNA)-based cytomegalovirus (CMV) test:
This article was originally published in Clinica
Executive Summary
Murex (Canada) has launched its DNA-based hybrid capture test for cytomegalovirus in Europe. The kit, which gives a quantitative, same-day result, was developed in collaboration with Digene Diagnostics. Murex hopes the availability of a quantitative test will open up a market for treatment monitoring in immunocompromised patients. The kit will be sold only for research use in France, Italy, Spain and the UK, but Murex hopes to launch it for diagnostic use in June. A 510(k) submission in the US is not expected before 1996.